Search results
Results from the WOW.Com Content Network
Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.
Rejoyn is a prescription-only digital therapeutic smartphone app approved by the US FDA for the treatment of major depressive disorder (MDD) in adults ages 22 and up. [1] It is prescribed in conjunction with standard antidepressant medication and professional guidance and support.
The staff reviewers said the available safety data for the device made by ReCor, a unit of Otsuka Holdings, did not raise concerns, while pointing that there was limited long-term data.
Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc. 08/01/2024 04:01 -0400 - Transaction Includes JNT-517, a Potential First-In-Class Oral Treatment for Phenylketonuria (PKU) -
TOKYO (Reuters) -Japan's Otsuka Pharmaceutical said on Thursday it agreed to pay more than $1 billion to acquire Jnana Therapeutics as it looks to expand its drug pipeline and research base in the ...
The device is made by Japanese company Otsuka's unit ReCor and is indicated for use in patients whose hypertension, or high blood pressure, cannot be controlled with drugs. US FDA approves Otsuka ...
In 2011, Astex Therapeutics Limited and SuperGen, Inc. (US) merged. [10] Following the acquisition, SuperGen, Inc. changed its name to Astex Pharmaceuticals, Inc., and began trading under the ticker symbol ASTX on NASDAQ. [11] The combined Astex entities were subsequently acquired by Otsuka Pharmaceutical in October 2013 for around USD $900 ...
Akebia Therapeutics Inc (NASDAQ: AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat. Otsuka sent a written notice to ...